spacer
home > epc > Spring 2014
PUBLICATIONS

European Pharmaceutical Contractor

epc
Spring 2014

   
Text
PDF
bullet
Keynote
Editor’s Letter

Casting his eye over the drug safety and patient recruitment articles in this edition, Graham Hughes reflects on the need to evolve relationships, both with industry partners and patients.
 
view
download pdf
bullet
Business and Finance
Financial Technologies

Cause for Control


With fragmented and manual payment processes a continuing burden for trial partners, Linda Drumright at IMS Health and Greenphire’s Sam Whitaker highlight closed-loop payment optimisation techniques that can better manage investigator budgets and complete the payment cycle.
 
view
download pdf
bullet
Marketplace & Business
Sponsor-CRO Collaborations

Double Impact


With the demands of global biopharma hitting unprecedented levels, the need to truly evolve the sponsor-CRO relationship and shed reliance on traditional, limited outsourcing models is becoming an imperative. Andrew Townshend and Judy Swilley at INC Research report.
 
view
download pdf
Strategic Collaborations

Kinks in the Chain


Beverley Flynn at Stevens & Bolton LLP emphasises the need for a flexible and integrated approach in order to assemble an efficient, high-quality supply chain between third-party manufacturing, R&D, logistics and warehousing.
 
view
download pdf
bullet
Clinical Trials: Patient Recruitment & Retention
Trial Recruitment

A Rare Find

Recruitment and retention can be a hard task for most clinical trials, but when the study area is an ultra-rare disease like alkaptonuria, every patient really does count, says Hana Ayoob at the AKU Society.
 
view
download pdf
bullet
Clinical Trials
Global Clinical Trials

Think Big

Operating in a global landscape means that clinical research has to consider a host of issues around ethics, contracts, logistics, start-up and data collection, says Rick Morrison from Comprehend Systems.
 
view
download pdf
bullet
Legal & Regulatory
EU Pharmacovigilance

Recent Developments

Shuna Mason
of CMS summarises the latest revisions to pharmacovigilance legislation, and other EU-led moves to accelerate and increase the updating of product and patient information with essential safety data.
 
view
download pdf
Annex 16: Revised

Quality First

Peter Gough
at NSF International navigates us through the European Commission’s draft revision of Annex 16, explaining the Good Manufacturing Practice changes to Qualifi ed Person responsibilities and batch release.
 
view
download pdf
bullet
Clinical Trials Supplies
Trial Drug Supply: APAC

Chain Reaction


Conducting trials in the Asia-Pacific is becoming more and more common, but the huge diversity of the region can lead to logistical problems. Kevin Cheong and Michelle Foust at Almac explain why selecting the right partner is essential to achieving effi ciencies.
 
view
download pdf
bullet
Electronic Solutions
Compliance Programmes

Do the Right Thing


Pharma invests heavily in compliance, and yet it is still no stranger to scandals and government investigations. Seth Berman at Stroz Friedberg discusses how tailored training, policies and software can help reinforce a culture of compliance from the top down.
 
view
download pdf
bullet
IT Solutions
Signal Detection

Sign of the Times


The benefits of a visualisation platform in signal detection can be significant. PRA’s Jacinta Aniagolu-Johnson explores how they can bolster routine and ad hoc review methods through simultaneous signal screening of individual case safety report and aggregate data.
 
view
download pdf
bullet
Science & Innovation: Asthma Focus
Asthma Management

Breathe Easy


Some 30 million people in Europe suffer from asthma, yet treatments are not always appropriate for the breadth of symptoms and sub-types. Samantha Walker at Asthma UK outlines the social costs and points to a new research partnership to galvanise collective expertise.
 
view
download pdf
bullet
Therapeutic Innovation: Cancer Focus
Automated Colony Analysis

Counting Costs

Michael Rau
from Oxford Optronix describes how CROs can use automated colony counting systems to resolve the capacity and scalability conundrum – ensuring they remain fl exible and costeffective in areas such as colony forming cell assays.
 
view
download pdf
bullet
DATA MANAGEMENT
Data Protection

A Safe Direction


New guidance aims to help pharma companies meet the often competing regulatory requirements of adverse event reporting and data protection. William Long at Sidley Austin outlines its recommendations and how it can be applied to everyday business practices.

 
view
download pdf
bullet
Risk Management
Business Protection

Risk Analysis


Large-scale outsourcing of research functions is predicted to transform the market over the next few years. Small- and medium-sized players are waiting to take advantage but, as Euan McKenzie of Central Insurance advises, there are both opportunities and risks to consider.
 
view
download pdf
bullet
Review
In Conclusion

No Kidding

Graham Hughes
comments on government plans to ban smoking in cars carrying children in England, and a call to update European requirements for paediatric trials.
 
view
download pdf

Interview
Industry Interview

The Extra Mile


From Microbiologist to Head of the Major Clinical Trial Unit, Sue Lee at World Courier tells EPC about her career and the push towards new markets.
 
view
download pdf
   
spacer



Published quarterly in
February, May,
August and November

News and Press Releases

YHEC announces the promotions of Michelle Jenks and Rachael McCool to the role Project Director

YHEC is pleased to announce the promotions of Michelle Jenks from the Economic Modelling team and Rachael McCool from the Systematic Reviewing team to the role Project Director. Michelle has a Master’s degree (MSc) in health economics from the University of York and has conducted economic evaluations and systematic reviews for both public and private sector clients. Michelle is the lead modeller in YHEC’s role as an External Assessment Centre for NICE and has also led on a range of economic evaluations conducted for clients within industry, such as cost-utility models and budget impact models. She often leads the development of early economic analyses to inform clinical trial design and pricing strategy.
More info >>

White Papers

Clinical Trials in Russia Orange Paper: 2nd Quarter 2014

Synergy Research Group

The Ministry of Health of Russian Federation approved 194 new clinical trials of all types including local and bioequivalence studies during the 2nd Quarter of 2014 (3% less than at the same period of the last year). The main contribution to the total number of studies was made by multinational multi-center clinical trials (MMCT) and the number of these studies stayed the same as in Q2 2013 – 81 studies. The number of bioequivalence studies (BE) decreased from 76 studies in Q2 2013 to 59 in Q2 2014, a 22% decrease from last year’s figure. The number of local clinical trials (LCT) increased from 42 in Q2 2013 to 54 clinical trials in Q2 2014.
More info >>

Industry Events

Global Bioproduction Summit, 5th-6th February 2018

5-6 February 2018, Hilton San Diego Resort & Spa, CA

After 15 years in Europe, the Global Bioproduction Summit moved to its new home of San Diego in 2016. The Bioproduction Summit delves deep into the world of biological production.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement